Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12617001257358
Ethics application status
Approved
Date submitted
24/08/2017
Date registered
29/08/2017
Date last updated
29/08/2017
Type of registration
Retrospectively registered

Titles & IDs
Public title
Reducing the Use of Sedative medication in aged care facilities: Implementation of the ‘RedUSe’ project into everyday practice.
Scientific title
Reducing the Use of Sedative medication in aged care facilities: Implementation of the ‘RedUSe’ project into everyday practice on the prevalence rates of regularly charted antipsychotics and benzodiazepines.
Secondary ID [1] 292732 0
nil known
Universal Trial Number (UTN)
Trial acronym
Linked study record
the proof of concept or pilot trial for this study was the RedUSe study(ACTRN12608000221358)

Health condition
Health condition(s) or problem(s) studied:
overuse of psychotropic agents in older residents of residential aged care facilities 304497 0
Condition category
Condition code
Mental Health 303833 303833 0 0
Other mental health disorders
Public Health 303834 303834 0 0
Health service research

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
The RedUSe (Reducing Use of Sedatives) intervention is a multi-strategic inter-professional program for RACFs. The program aims to ensure the appropriate use and review of two specific classes of psychotropic medications, antipsychotics and benzodiazepines.
The program lasts for 6 months, commencing with a psychotropic audit of all resident's medication. The prevalence findings are presented to all staff at an interactive case-based group educational session, which is then followed by a targeted psychotropic review process involving a pharmacist, nurse and the resident’s prescriber. The full program was delivered to all 150 participant RACFs for the a 6-month period.
To begin with, psychotropic audit measures were taken at baseline and 3 months, with a final follow-up audit performed at 6 months. The audit was performed using a specially designed program which collected prescribing data from supply pharmacy packing programs. The data was validated by a nurse at each home and when de-identified, was re-checked by researchers.
All Educational sessions were delivered by trained consultant pharmacists already providing services to the RACF (the pharmacists attended a one-day training program in a group). These two 1 hour educational sessions were held at the RACF location after the first audit (baseline), and again after the 3 month audit. At each educational session, all staff were provided with a printed set of guidelines, a workbook and were then asked to view a video on evidence-based psychotropic use in older people and finally, to also view a customised PowerPoint presentation when each RACF's psychotropic audit results were presented, along with didactic information about antipsychotic and benzodiazepine use in older people. Session 1 at baseline was more general but session 2 involved case-studies and more discussion between attendees. Before the first educational session, all attendees were asked to complete a validated knowledge quiz. The same quiz was offered to attending staff at the end of the second educational session.
The psychotropic review process was then performed for each resident taking psychotropic medications after the education sessions were held, specifically at baseline and at 3 months. This process involved the consultant pharmacist (same one as gave the training) providing their written information on a form, followed by a recommendation from a trained 'champion' nurse (training for 4 hours as a group) and finally, the GP or prescriber read the form and acted on the information if the judged this necessary. Researchers were not able to access these forms as they contained identifiable clinical information and names of health providers.
Intervention code [1] 298973 0
Treatment: Other
Intervention code [2] 298976 0
Treatment: Drugs
Comparator / control treatment
No control group according to research funding rules
Control group
Uncontrolled

Outcomes
Primary outcome [1] 303195 0
Prevalence of regularly charted antipsychotics across the RACFs using data from supply community pharmacy packing programs which was collected using a customised computer IT program.
Timepoint [1] 303195 0
Baseline, 3 months and 6 months post intervention commencement. The 6-month measure was the primary timepoint.
Primary outcome [2] 303209 0
Prevalence of regularly charted benzodiazepines across the RACFs using data from supply community pharmacy packing programs which was collected using a customised computer IT program.
Timepoint [2] 303209 0
Baseline, 3 months and 6 months post intervention commencement. The 6-month measure was the primary time point.
Secondary outcome [1] 338205 0
Mean chlorpromazine equivalent doses per resident per day for each RACF. This outcome was calculated using prescribing data collected from community pharmacy packing programs and also programmed into the IT computer program.
Timepoint [1] 338205 0
Baseline, 3 months and 6 months post intervention commencement.
Secondary outcome [2] 338206 0
Number of antipsychotic dosage reduction/cessation attempts using the prescribing data collected from community pharmacy packing programs.
Timepoint [2] 338206 0
At 3 months and 6 months post intervention commencement.
Secondary outcome [3] 338207 0
Proportion of sedative reduction attempts maintained from 3 to 6 months to assess the extent of ‘rebounds’. This data was collected from community pharmacy packing programs via a customised computer program.
Timepoint [3] 338207 0
At 6 months post intervention commencement.
Secondary outcome [4] 338246 0
Mean diazepam equivalent doses per resident per day for each RACF. This outcome was calculated using prescribing data collected from community pharmacy packing programs and also programmed into the IT computer program.
Timepoint [4] 338246 0
Baseline, 3 months and 6 months post intervention commencement.
Secondary outcome [5] 338247 0
Number of benzodiazepam dosage reduction/cessation attempts using the prescribing data collected from community pharmacy packing programs.
Timepoint [5] 338247 0
At 3 months and 6 months post intervention commencement.
Secondary outcome [6] 338248 0
Proportion of sedative reduction attempts maintained from 3 to 6 months to assess the extent of ‘rebounds’. This data was collected from community pharmacy packing programs via a customised computer program.
Timepoint [6] 338248 0
At 6 months post intervention commencement.
Secondary outcome [7] 338249 0
Nursing staff Psychotropic knowledge acquisition using the validated old age psychotropic Quiz. This was provided as a paper-based anonymized form.
Timepoint [7] 338249 0
Staff completed the quiz at the start of the first educational session and repeated the same quiz at the end of the second 3-month training session post commencement.
Secondary outcome [8] 338250 0
Feedback questionnaire on the educational session - paper based form asking seven questions and asking staff to rank the training using simple 5 point Likert scales. Staff were also asked to list the component of the educational session they felt was the most valuable, and also invited to make suggestions for improvement.
Timepoint [8] 338250 0
Conducted at the end of every educational session at baseline and the three months post intervention commencement.

Eligibility
Key inclusion criteria
All permanent residents of RACF whether they were taking medication or not.
Minimum age
60 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
RACF residents in respite care or those receiving active palliation

Study design
Purpose of the study
Educational / counselling / training
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Type of endpoint/s
Statistical methods / analysis
The distribution of the RedUSe LTC facility sample was compared to the expected national distribution based on Federal aged care data from 2014/2015 using a Pearson’s chi squared goodness-of-fit test. The prevalence of use for each psychotropic class was expressed as the mean facility percentage of residents, with confidence intervals. Changes in psychotropic drug class use over time were estimated using linear mixed effects models. Due to differences in extent of medication use across facilities, random slopes and intercepts were modelled for each facility to account for these uncontrolled effects. Model assumptions were checked using standard graphical methods, including examination of residuals. All statistical analyses were computed in the R statistical environment (R-3.3.2 for Windows).[The R Foundation. The R Project for Statistical Computing. Available at: https://www.r-project.org/. Accessed March 1, 2017.]
Linear mixed effects models were fitted using the ‘lme4’ R package. [Bates D, Mächler M, Bolker B, Walker S. Fitting linear mixed-effects models using lme4. arXiv preprint arXiv:14065823 2014.]
Multiple comparison tests were performed with ‘multcomp’ R. [Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biometrical J 2008;50:346-63.]

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
Actual
3/03/2014
Date of last participant enrolment
Anticipated
Actual
30/10/2015
Date of last data collection
Anticipated
Actual
15/04/2016
Sample size
Target
150
Accrual to date
Final
150
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,TAS,WA,VIC

Funding & Sponsors
Funding source category [1] 297369 0
Government body
Name [1] 297369 0
Australian Government Department of Health
Country [1] 297369 0
Australia
Primary sponsor type
University
Name
University of Tasmania
Address
Private bag 143, Hobart Tas 7001
Country
Australia
Secondary sponsor category [1] 296346 0
None
Name [1] 296346 0
Address [1] 296346 0
Country [1] 296346 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 298473 0
Tasmanian Health and Medical Human Research Ethics Committee EC00337
Ethics committee address [1] 298473 0
Ethics committee country [1] 298473 0
Australia
Date submitted for ethics approval [1] 298473 0
01/09/2013
Approval date [1] 298473 0
28/10/2013
Ethics approval number [1] 298473 0
Ethics Ref No: H0013545

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes
Attachments [1] 1993 1993 0 0
/AnzctrAttachments/373533-RedUse.Executive.Summary. Final.pdf (Publication)

Contacts
Principal investigator
Name 77190 0
Dr Juanita Westbury
Address 77190 0
Wicking Dementia Research and Education Centre
Locked Bag 143
Hobart TAS 7001
Country 77190 0
Australia
Phone 77190 0
+61362261966
Fax 77190 0
Email 77190 0
[email protected]
Contact person for public queries
Name 77191 0
Juanita Westbury
Address 77191 0
Wicking Dementia Research and Education Centre
Locked Bag 143
Hobart TAS 7001
Country 77191 0
Australia
Phone 77191 0
+61362261966
Fax 77191 0
Email 77191 0
[email protected]
Contact person for scientific queries
Name 77192 0
Juanita Westbury
Address 77192 0
Wicking Dementia Research and Education Centre
Locked Bag 143
Hobart TAS 7001
Country 77192 0
Australia
Phone 77192 0
+61362261966
Fax 77192 0
Email 77192 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseRedUSe: Reducing antipsychotic and benzodiazepine prescribing in residential aged care facilities.2018https://dx.doi.org/10.5694/mja17.00857
N.B. These documents automatically identified may not have been verified by the study sponsor.